Renin-Angiotensin System in Diabetes

The renin-angiotensin system (RAS) is pivotal in regulating blood pressure and fluid balance, but its dysfunction is increasingly recognized in the context of diabetes. In individuals with diabetes, particularly those with concurrent hypertension, the RAS becomes overactive, resulting in elevated levels of angiotensin II. This increase contributes to several adverse effects, including insulin resistance, inflammation, and endothelial dysfunction. Such dysregulation can worsen both microvascular and macrovascular complications associated with diabetes. Commonly prescribed medications, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), not only help manage hypertension in diabetic patients but may also enhance insulin sensitivity and safeguard renal function. A thorough understanding of the relationship between the RAS and diabetes is critical for developing integrated treatment approaches that simultaneously address hypertension and metabolic control, thereby reducing the risk of complications in individuals with diabetes.